HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Generalized anxiety disorder — Clinical Guidelines

Overview

Generalized Anxiety Disorder (GAD) is characterized by excessive, uncontrollable worry about everyday things, occurring on more days than not for at least six months, accompanied by physical symptoms like restlessness, fatigue, and difficulty concentrating 7.

Diagnosis

Key diagnostic criteria include persistent and excessive worry about various domains, occurring on more days than not for at least six months 7.

No specific laboratory tests; diagnosis primarily clinical based on DSM-5 criteria 7.

Imaging studies like voxel-based morphometry may show modest grey matter alterations in the left superior temporal gyrus 2.

Management

First-line treatments: Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) are commonly prescribed 4.

Adjunctive treatments: Benzodiazepines may be used as an add-on to antidepressants in the initial weeks or as standalone therapy 1.

Emerging therapies: Non-invasive brain stimulation techniques such as rTMS, cTBS, and tDCS show promise with significant reductions in Hamilton Anxiety Rating Scale (HARS) scores 3.

Special Populations

Pregnancy: Limited specific guidance provided in abstracts; SSRIs are often preferred over benzodiazepines due to safety profiles 4.

Pediatrics: No significant grey matter alterations identified in adolescent GAD subgroup, but anxiety severity correlates with insula alterations 2.

Elderly: No specific details provided in abstracts regarding unique considerations or treatment adjustments for elderly patients.

Comorbidities: Common comorbidities include depression and other anxiety disorders; management should address these concurrently 4.

Key Recommendations

Initiate treatment with SSRIs or SNRIs as first-line pharmacotherapy for GAD (Evidence: Strong 4).

Consider benzodiazepines as an adjunctive therapy in the short term, particularly during initial weeks of treatment (Evidence: Moderate 1).

Explore non-invasive brain stimulation techniques for patients who do not respond adequately to pharmacotherapy (Evidence: Moderate 3).

Monitor and manage comorbidities, such as depression, alongside GAD treatment (Evidence: Expert opinion 4).

Be cautious with pregabalin use due to potential for abuse and dependence, especially in populations at higher risk (Evidence: Weak 5).

References

1 Fernandes H, Novais C, Sousa-Pinto B, Soares-da-Silva P, Azevedo LF. Comparative Efficacy and Safety of Benzodiazepines in the Treatment of Patients with Generalized Anxiety Disorder: A Systematic Review and Network Meta-Analysis. Psychotherapy and psychosomatics 2025. link 2 Ou CH, Cheng CS, Lin PL, Lee CL. Grey matter alterations in generalized anxiety disorder: A voxel-wise meta-analysis of voxel-based morphometry studies. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 2024. link 3 Qi L, Wang S, Li X, Yu Y, Wang W, Li Q et al.. Non-invasive brain stimulation in the treatment of generalized anxiety disorder: A systematic review and meta-analysis. Journal of psychiatric research 2024. link 4 Sandelin R, Kowalski J, Ahnemark E, Allgulander C. Treatment patterns and costs in patients with generalised anxiety disorder: one-year retrospective analysis of data from national registers in Sweden. European psychiatry : the journal of the Association of European Psychiatrists 2013. link 5 Gahr M, Freudenmann RW, Hiemke C, Kölle MA, Schönfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. European journal of clinical pharmacology 2013. link 6 Kirkwood K. A numbered day in the life. Journal of hospital medicine 2009. link 7 Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K et al.. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. The Journal of clinical psychiatry 2001. link 8 Willmuth LR, Weaver L, Donlan S. Utilization of medical services by transferred employees. Differential effect of life change on health. Archives of general psychiatry 1975. link

Generalized anxiety disorder